Sherbrooke Park Advisers LLC Fulcrum Therapeutics, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 45,157 shares of FULC stock, worth $170,241. This represents 0.07% of its overall portfolio holdings.
Number of Shares
45,157
Previous 227,225
80.13%
Holding current value
$170,241
Previous $811 Million
73.84%
% of portfolio
0.07%
Previous 0.19%
Shares
3 transactions
Others Institutions Holding FULC
# of Institutions
130Shares Held
51.6MCall Options Held
1.04MPut Options Held
32.6K-
Ra Capital Management, L.P. Boston, MA10.2MShares$38.6 Million0.78% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$19.8 Million4.03% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$18.1 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$18 Million1.13% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.34MShares$12.6 Million0.65% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $196M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...